S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters

In parallel with vaccination, oral antiviral agents are highly anticipated to act as countermeasures for the treatment of the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Oral antiviral medication demands not only high antiviral...

Descripción completa

Detalles Bibliográficos
Autores principales: Sasaki, Michihito, Tabata, Koshiro, Kishimoto, Mai, Itakura, Yukari, Kobayashi, Hiroko, Ariizumi, Takuma, Uemura, Kentaro, Toba, Shinsuke, Kusakabe, Shinji, Maruyama, Yuki, Iida, Shun, Nakajima, Noriko, Suzuki, Tadaki, Yoshida, Shinpei, Nobori, Haruaki, Sanaki, Takao, Kato, Teruhisa, Shishido, Takao, Hall, William W., Orba, Yasuko, Sato, Akihiko, Sawa, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765455/
https://www.ncbi.nlm.nih.gov/pubmed/36327352
http://dx.doi.org/10.1126/scitranslmed.abq4064

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765455/
https://www.ncbi.nlm.nih.gov/pubmed/36327352
http://dx.doi.org/10.1126/scitranslmed.abq4064

Ejemplares similares